

10 March 2025

## Investment from Sichuan Hebang Biotechnology

### Highlights

- **Avenira Limited** (ASX: AEV) (“**Avenira**” or “**the Company**”) has secured a further significant investment commitment from its largest shareholder, Hebang Biotechnology (Hong Kong) Investment Limited (“**Hebang**”), being a wholly-owned subsidiary of Sichuan Hebang Biotechnology Corporation Limited (SHSE: 603077)(“**Sichuan Hebang**”).
- The Investment comprises:
  - A\$7.567 million Placement at an issue price of A\$0.007 per new share subject to shareholder approval and any other required regulatory approvals (“**Placement**”).
  - Pending shareholder and any other required regulatory approvals for the Placement, Hebang has also agreed to provide an unsecured draw down loan facility.
  - Funds from the drawn down loan facility and the Placement will be used for progressing the DSO Project and for general working capital.

### Investment

- **Placement:** Subject to shareholder approval and any other required regulatory approvals on or before 30 May 2025 the Placement will raise A\$7.567 million through the issue of 1,081,000,000 shares at an issue price of \$0.007 per share. This issue will result in Hebang having increasing its interest in the issued capital of the Company to 49%,
- **Unsecured loan:** Hebang has agreed to provide an unsecured draw down loan facility pending shareholder approval and any other required regulatory approvals for the Placement. The terms of the loan are:
  - Available Facility - \$7.567 million;
  - Drawdown minimum amounts of \$2m at a time (except for final draw down);
  - Repayment – Repayment of principal and interest upon completion of the Placement or if the Placement is not completed within 12 months after the date of the first draw down;
  - Interest – 12% pa capitalised and payable on repayment of principal

Commenting on the Strategic Investment, Avenira Deputy Chairman, Brett Clark stated:

*"We are delighted that Hebang, our principal shareholder, has chosen a further investment in Avenira. This enhanced cooperation with Hebang provides Avenira the opportunity to accelerate the DSO Project targeting delivery of ore to port by late 3<sup>rd</sup>Qtr / early 4<sup>th</sup> Qtr this calendar year, substantially enhancing the value of the Wonarah resource.*

*On behalf of Avenira's board and management, I would like to express our gratitude to shareholders for their ongoing support as we advance the development of our significant phosphate resource."*

Comment from Mr Zhenggang He, Actual Controller - Sichuan Hebang Biotechnology Co., Ltd.:

*"Our enduring strategic partnership with Avenira is growing stronger, highlighting Hebang's lasting dedication to the company's progress. We believe this financial backing will propel the development of Avenira's Wonarah project. Hebang remains wholly committed to Avenira's success, and we are eager to enhance our collaboration as the project moves forward."*

**This announcement was authorised for release by the Board of Directors.**

For further information, contact:

**Brett Clark**  
Deputy Chairman  
+61 8 9264 7000